BioCentury
ARTICLE | Targets & Mechanisms

APC mutants for ALS

November 19, 2009 8:00 AM UTC

A study by University of Rochester researchers suggests that a modified form of activated protein C could be used to treat a common form of familial amyotrophic lateral sclerosis.1 The findings also suggest that inflammatory activation of microglia could be an early intervention point to stop the disease.

The findings are licensed to ZZ Biotech LLC, which was cofounded in 2008 by study leader Berislav Zlokovic. The company is optimizing the activated protein C (APC) variant to maximize its anti-inflammatory effects and reduce its anticoagulant activity...